Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.262
Index Copernicus (ICV) – 155.19, MNiSW – 15
Rejection rate – 65.13%
License – Creative Commons (CC BY-NC-ND 4.0)
ISSN 1899–5276 (print),   ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 4, July-August, p. 775–779

doi: 10.17219/acem/60098

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Plasmatic microRNA as Potential Biomarkers of Multiple Sclerosis: Literature Review

Magdalena J. Kacperska1,A,B,D,E,F, Jakub Walenczak2,E, Bartłomiej Tomasik3,A,F

1 Department of Neurology and Stroke, Medical University of Lodz, Poland

2 Medical University of Lodz, Poland

3 Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland

Abstract

There is ongoing research with the goal of finding precise and sensitive biomarkers of multiple sclerosis (MS). Recently, researchers have paid particular attention to small, non-encoding, single stranded endogenous microRNA molecules (miR, miRNA). At first these molecules were thought to be found only within the cell. Today it is known, however, that they can also be found in the extracellular spaces (plasma, serum, saliva, urine, tears, sweat, milk, sperm and amniotic fluid, among others). It has been established that extracellular miRNA perform a wide spectrum of functions, such as transmitting signals between cells, modulating processes involved in angiogenesis, neurogenesis, proliferation or apoptosis. Given the high stability of these small molecules in the extracellular compartment (plasma), their tissue specificity and strong ties with pathological processes underlying multiple sclerosis, miRNA seem to be a good target for researchers trying to discover diseases’ new markers. Determining an accurate miRNA expression profile in MS and correlating it with the gene profile may lead to the discovery of new pathophysiological processes. Demonstrating that changes in the composition and concentration of extracellular miRNA may in some cases correlate with certain aspects of the underlying disease (such as its severity) could lead to their use as biomarkers of MS. Further research is needed.

Key words

multiple sclerosis, plasma miRNA, biomarkers, role of miRNA in MS

References (32)

  1. Ouellet DL, Perron MP, Gobella LA, Plante P, Provest P: MicroRNA in gene regulation: When the smallest Governs It All. J Biomed Biotechnol (on-line) 2006, article ID 69616, 1–20.
  2. Hukowska-Szematowicz B, Deptuła W: Biologiczna rola mikroRNA (miRNA) – nowe dane. Post Biol Kom 2010, 3, 585–597.
  3. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 2004, 116, 281–229.
  4. Rolle K, Gabryelska M, Wyszko E: Niekodujące RNA w centralnym układzie nerwowym ssaków. Neuroskop 2008, 10, 96–105.
  5. Starega-Roslan J, Koscianska E, Kozlowski P: The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci 2011, 68, 2859.
  6. Recchioni R, Marcheselli F, Olivieri F: Conventional and novel diagnostic biomarkers of acute myocardial infarction: A promising role for circulating microRNAs. Biomarkers 2013, 18, 547–558.
  7. Kacperska MJ, Jastrzębski K, Kozera-Kępiniak A: Wybrane farmakokinetyczne interakcje leków w trakcie leczenia padaczki. Część I. Aktual Neurol 2013, 13, 40–49.
  8. Vickers KC, Palmisano BT, Shoucri BM: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13, 423–433.
  9. Redis RS, Calin S, Yang Y: Cell-to-cell miRNA transfer: From body homeostasis to therapy. Pharmacol Therapeut 2012, 136, 169–174.
  10. Fic P, Kowalczuk K, Grabarska A: Mikro-RNA − nowe szanse diagnostyczne w chorobie niedokrwiennej i zawale serca. Postepy Hig Med Dosw 2014, 68, 410–418.
  11. Keller A, Leidinger P, Bauer A, Elsharawy A: Toward the blood-borne miRNome of human diseases. Nat Methods 2011, 8, 841–843.
  12. Kułakowska A, Bartosik-Psujek H, Hożejowski R: Selected aspects of the epidemiology of multiple sclerosis in Poland – a multicentre pilot study. Neurol Neurochir Pol 2010, 44, 443–452.
  13. Kacperska MJ, Jastrzebski K, Tomasik B, Walenczak J, Konarska-Krol M, Glabinski A: Selected extracellular microRNA as Potential Biomarkers of Multiple Sclerosis Activity – Preliminary Study. J Mol Neurosci. DOI 10.1007/s12031-014-0476-3.
  14. Junker A, Hohlfeld R, Meinl E: The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol 2011, 7, 56–59.
  15. Martinelli-Boneschi F, Fenoglio C, Brambilla P: MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett 2012, 508, 4–8.
  16. Tufekci KU, Oner MG, Genc S: MicroRNAs and multiple sclerosis. Autoimmune Dis 2011, 2011, 807426.
  17. Lindberg RLP, Hoffmann F, Mehling M: Altered expression of miR-17-5p in CD4+ lymphocytes of relapsingremitting multiple sclerosis patients. Eur J Immunol 2010, 40, 888–898.
  18. Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Griffiths L: Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 2012, 39, 6219–6225.
  19. Fenoglio C, Ridolfi E, Galimberti D: MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci 2012, 13, 13227–13239.
  20. Gandhi R, Healy B, Gholipour T: Circulating microRNAs as biomarkers disease staging in multiple sclerosis. Ann Neurol 2013, 73, 729–740.
  21. Ksiazek-Winiarek DJ, Kacperska MJ, Glabinski A: MicroRNAs as novel regulators of neuroinflammation. Mediators Inflamm 2013, 172351.
  22. O’Connor KC, Appel H, Bregoli LI: Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005, 175, 1974–1982.
  23. Turchonovich A, Weiz L, Langheinz A: Characterization of extracellular circulating microRNA. Nucleid Acids Res 2011, 39, 7223–7233.
  24. Ventura A, Young AG, Winslow MM: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132, 875–886.
  25. Eis PS, Tam W, Sun L: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005, 102, 3627–3632.
  26. Rodriguez A, Vigorito E, Clare S: Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316, 608–611.
  27. Jing Q, Huang S, Guth S: Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 2005, 120, 623–634.
  28. Keklikoglou I, Koerner C, Schmidt C: MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene 2011, 31, 4150
  29. Sheedy FJ, O’Neill LA: Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann Rheim Dis 2008, 67, iii50.
  30. Baczyńska D, Michałowska D, Witkiewicz W: Rola mikroRNA w chorobach niedokrwiennych – wpływ na regulację procesów zapalnych, apoptozy i angiogenezy. Prz Lek 2014, 70, 3.
  31. Suarez Y, Wang C, Manes TD: Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: Feedback control of inflammation. J Immunol 2010, 184, 21.
  32. Liston A, Linterman M, Lu LF: MicroRNA in the adaptive immune system, in sickness and in health. J Clin Immunol 2010, 30, 339–346.